NewsBenzingaMesa Laboratories prévoit des ventes pour l’exercice 2027 de 250,000 M$ à 255,000 M$, contre 254,450 M$ estimés. Mesa Laboratories prévoit des ventes pour l’exercice 2027 de 250,000 M$ à 255,000 M$, contre 254,450 M$ estimés. Benzinga 2026.11.09 22:37 (GMT+0) Open on Benzinga Other news StoneX Maintains Buy on Rivian Automotive, Lowers Price Target to $20 Amer Sports Unleashes $1 Billion Buyback, Raises 2026 Outlook EXCLUSIVE: Tesla Still Rules Leveraged ETFs, but Anthropic IPO and Micron’s Rise Signal What’s Next StoneX Reiterates Hold on iQIYIto Hold StoneX Maintains Buy on Baidu, Lowers Price Target to $125 Veru Presents New Results At ObesityWeek; Adding Enobosarm Preserved Lean Mass And Stair Climb Physical Function In Older Patients ≥65 Years With Obesity Receiving Semaglutide
Veru Presents New Results At ObesityWeek; Adding Enobosarm Preserved Lean Mass And Stair Climb Physical Function In Older Patients ≥65 Years With Obesity Receiving Semaglutide